BALB/c nude Publications

BALB/c nude Model Page

Filter publications by application: All Breast Cancer Lung Cancer Lymphoma Oncology
Filter publications by model type: All

Author(s)

(Date)

Paper Title

Citation

Model Type

Applications

Full Text

Martínez AK, et al.
Mouse over for full list
Martínez AK, Jensen K, Hall C, O'Brien A, Ehrlich L, White T, Meng F, Zhou T, Greene J, Bernuzzi F, Invernizzi P, Dostal DE, Lairmore T, Alpini G, Glaser S
(2017) Nicotine Promotes Cholangiocarcinoma Growth in Xenograft Mice. Am. J. Pathol.
Oncology
Jensen SS, et al.
Mouse over for full list
Jensen SS, Petterson SA, Halle B, Aaberg-Jessen C, Kristensen BW
(2017) Effects of the lysosomal destabilizing drug siramesine on glioblastoma in vitro and in vivo. BMC Cancer 17(1):178
Oncology
Shiraki K, et al.
Mouse over for full list
Shiraki K, Tsuji N, Shioda T, Isselbacher KJ, Takahashi H
(1997) Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc. Natl. Acad. Sci. U.S.A. 94(12):6420-5
Sarek G, et al.
Mouse over for full list
Sarek G, Kurki S, Enbäck J, Iotzova G, Haas J, Laakkonen P, Laiho M, Ojala PM
(2007) Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J. Clin. Invest. 117(4):1019-28
Lymphoma
Rakhmilevich AL, et al.
Mouse over for full list
Rakhmilevich AL, Hooper AT, Hicklin DJ, Sondel PM
(2004) Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody. Mol. Cancer Ther. 3(8):969-76
Breast Cancer
Qin XQ, et al.
Mouse over for full list
Qin XQ, Tao N, Dergay A, Moy P, Fawell S, Davis A, Wilson JM, Barsoum J
(1998) Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 95(24):14411-6
Oncology
Herbert LM, et al.
Mouse over for full list
Herbert LM, Grosso JF, Dorsey M, Fu T, Keydar I, Cejas MA, Wreschner DH, Smorodinski N, Lopez DM
(2004) A unique mucin immunoenhancing peptide with antitumor properties. Cancer Res. 64(21):8077-84
Oncology
Hassid Y, et al.
Mouse over for full list
Hassid Y, Furman-Haran E, Margalit R, Eilam R, Degani H
(2006) Noninvasive magnetic resonance imaging of transport and interstitial fluid pressure in ectopic human lung tumors. Cancer Res. 66(8):4159-66
Lung Cancer
Armentano D, et al.
Mouse over for full list
Armentano D, Smith MP, Sookdeo CC, Zabner J, Perricone MA, St George JA, Wadsworth SC, Gregory RJ
(1999) E4ORF3 requirement for achieving long-term transgene expression from the cytomegalovirus promoter in adenovirus vectors. J. Virol. 73(8):7031-4
Ariazi EA, et al.
Mouse over for full list
Ariazi EA, Lewis-Wambi JS, Gill SD, Pyle JR, Ariazi JL, Kim HR, Sharma CG, Cordera F, Shupp HA, Li T, Jordan VC
(2006) Emerging principles for the development of resistance to antihormonal therapy: implications for the clinical utility of fulvestrant. J. Steroid Biochem. Mol. Biol. 102(1-5):128-38
Aoki K, et al.
Mouse over for full list
Aoki K, Akyürek LM, San H, Leung K, Parmacek MS, Nabel EG, Nabel GJ
(2000) Restricted expression of an adenoviral vector encoding Fas ligand (CD95L) enhances safety for cancer gene therapy. Mol. Ther. 1(6):555-65